Prognostic and clinicopathological significance of long non-coding RNA in glioma
Growing evidence from recent studies have revealed that long non-coding RNA (lncRNA) might be a useful prognostic biomarker for glioma; we therefore conducted the current meta-analysis to evaluate prognostic and clinicopathological predictive value of lncRNA expression for glioma patients. Eligible studies were identified through multiple research strategies in PubMed, EMBASE, Web of Science, and Cochrane Library up to May 2017. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were utilized to calculate patient’s survival. Fourteen eligible studies with 1415 patients were ultimately included in this meta-analysis. Our meta-analysis showed a significant association between high lncRNA expression level and OS in glioma patients (HR 2.09, 95% CI 1.68–2.58, P < 0.001). Subgroup analysis was conducted to explore the potential heterogeneity. As for clinicopathological parameters, lncRNA expression was significantly associated with tumor diameter (< 3 vs ≥ 3 cm, OR 0.39, 95% CI 0.27–0.56, P < 0.001; < 5 vs ≥ 5 cm, OR 0.56, 95% CI 0.34–0.92, P = 0.02), tumor grade (OR 0.21, 95% CI 0.13–0.34, P < 0.001), and Karnofsky Performance Status Scale (OR 2.52, 95% CI 1.54–4.11, P < 0.001). LncRNA may serve as a biomarker for prognosis and clinicopathological features in glioma patients.
KeywordsLong non-coding RNA Glioma Prognosis Characteristic features
Study design: Yanhui Liu, Junhong Li, Ruofei Liang.
Literature search: Ruofei Liang, Chen Song, Yufan Xiang.
Data collection: Junhong Li, Ruofei Liang.
Statistical analysis: Junhong Li, Yufan Xiang.
Result interpretation: Yanhui Liu, Junhong Li, Ruofei Liang.
Manuscript preparation: Junhong Li, Ruofei Liang.
This study was supported by the Key Research and Development Project from the Department of Science and Technology of Sichuan Province, China (grant number 2017SZ0006). The sponsor had no role in the design or conduct of this research.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 2.Reon BJ, Anaya J, Zhang Y, Mandell J (2016) Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis. 13:e1002192. https://doi.org/10.1371/journal.pmed.1002192
- 11.Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, Zhang A, Jia Z, Wang G, Yu S, Pu P, Dong L, Kang C (2012) LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol 40:2004–2012. https://doi.org/10.3892/ijo.2012.1413 PubMedGoogle Scholar
- 18.Zhao W, Sun C, Cui Z (2017) A long noncoding RNA UCA1 promotes proliferation and predicts poor prognosis in glioma. Clin Transl Oncol. https://doi.org/10.1007/s12094-016-1597-7
- 19.Lv QL, Hu L, Chen SH, Sun B, Fu ML, Qin CZ, Qu Q, Wang GH, He CJ, Zhou HH (2016) A long noncoding RNA ZEB1-AS1 promotes tumorigenesis and predicts poor prognosis in glioma. Int J Mol Sci 17. https://doi.org/10.3390/ijms17091431
- 20.Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R, Pu P, Kang C, Han L (2016) A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett 373:251–259. https://doi.org/10.1016/j.canlet.2016.01.039 CrossRefPubMedGoogle Scholar
- 24.Jing SY, Lu YY, Yang JK, Deng WY, Zhou Q, Jiao BH (2016) Expression of long non-coding RNA CRNDE in glioma and its correlation with tumor progression and patient survival. Eur Rev Medical Pharmacol Sci 20:3992–3996Google Scholar
- 26.Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, Yu SZ, Pu PY, Liu N, You YP, Jiang T, Kang CS (2013) HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncology 15:1595–1603. https://doi.org/10.1093/neuonc/not131 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Zhang T, Wang YR, Zeng F, Cao HY, Zhou HD, Wang YJ (2016) LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675. Eur Rev Medical Pharmacol Sci 20:4891–4897Google Scholar
- 29.Zhuang JJ, Yue M, Zheng YH, Li JP, Dong XY (2016) Long non-coding RNA MVIH acts as a prognostic marker in glioma and its role in cell migration and invasion. Eur Rev Medical Pharmacol Sci 20:4898–4904Google Scholar
- 31.Hu L, Lv QL, Chen SH, Sun B, Qu Q, Cheng L, Guo Y, Zhou HH, Fan L (2016) Up-regulation of long non-coding RNA AB073614 predicts a poor prognosis in patients with glioma. Int J Environ Res Public Health 13:433. https://doi.org/10.1186/s13041-016-0226-2 10.3390/ijerph13040433CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Li J, Wang YM, Song YL (2016) Knockdown of long noncoding RNA AB073614 inhibits glioma cell proliferation and migration via affecting epithelial-mesenchymal transition. Eur Rev Medical Pharmacol Sci 20:3997–4002Google Scholar
- 39.Ke J, Yao YL, Zheng J, Wang P, Liu YH, Ma J, Li Z, Liu XB, Li ZQ, Wang ZH, Xue YX (2015) Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326. Oncotarget 6:21934–21949. https://doi.org/10.18632/oncotarget.4290 PubMedPubMedCentralGoogle Scholar
- 41.Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z, Liu Y (2015) Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett 359:75–86. https://doi.org/10.1016/j.canlet.2014.12.051 CrossRefPubMedGoogle Scholar